<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315519</url>
  </required_header>
  <id_info>
    <org_study_id>26</org_study_id>
    <nct_id>NCT04315519</nct_id>
  </id_info>
  <brief_title>Effect of Blood Flow Restricted Aerobic Exercise in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Investigation of the Effect of Blood Flow Restricted Aerobic Exercise on Cardiorespiratory Fitness and Blood Glucose in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recep Tayyip Erdogan University Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recep Tayyip Erdogan University Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the effect of low intensity blood flow restricted aerobic exercise on glycemic
      and respiratory status with moderate aerobic exercise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to show, whether the effect of low-intensity aerobic exercise
      training combined with blood flow restriction is similar on both glycemic and
      cardiorespiratory status compared to moderate-intensity continuous aerobic exercise, in
      individuals with &quot;type 2 diabetes mellitus&quot; .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Glucose</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Fasting Blood Glucose, this data will be collected from the individulas routine biochemistry tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Glycated hemoglobin, This data will be collected from teh individulas during routine test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Glucose in Oral glucose Tolerance Test</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Blood Glucose in Oral glucose Tolerance Test, this data will be collected from the individuals during routine tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiorespiratory Fitness</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Maximal Power in Maximal Exercise Test, this test will be performed in incremental cardiopulmonary exercise test in cycle ergometer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Strength of Quadriceps Muscle</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The Strength of Quadriceps Muscle, this data will be collected before the intervention eith a manual muscle tester, in sitting position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Free Mass</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Fat Free Mass will be calculated by bioimpedance analysis, this data will be collected with all individulas to see the changes with the muscle mass, the test will be The test will be carried out with a 4-channel test device, both hand and foot, to eveluate changes segmentally.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Strength of Hamstring Muscle</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The Strength of Hamstring Muscle, this data will be collected before the intervention eith a manual muscle tester, in sitting position.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Blood Flow Restricted Aerobic (BFRA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low intensity Aerobic exercise with Blood Flow Restriction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Aerobic Exercise (MAE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>moderate intensity aerobic exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Aerobic Exercise</description>
    <arm_group_label>Blood Flow Restricted Aerobic (BFRA)</arm_group_label>
    <arm_group_label>Moderate Aerobic Exercise (MAE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having Type 2 Diabetes

          -  Not have been recruited any exercise programme for 6 months

          -  Volunteering to participate in the study

        Exclusion Criteria:

          -  Nephropathy

          -  Retinopathy

          -  Have had myocardial infarction at least 6 months ago

          -  Stable or unstable angina pectoris

          -  The presence of peripheral artery disease

          -  Resting blood pressure above 160/100 mmHg

          -  Body mass index over 35 kg / m2

          -  History of deep vein thrombosis, pulmonary embolism or stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elif SAHIN</last_name>
    <phone>+90 (464) 344 20 45</phone>
    <email>fztelifsahin61@gmail.com</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Recep Tayyip Erdogan University Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Elif ŞAHİN</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Blood Flow Restricted Exercise</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Aerobic Exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

